Arbutus Biopharma Corporation (ABUS) Stock Analysis

Company Overview

Arbutus Biopharma Corporation (ABUS) is capitalised at $640.69M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 19 employees.

The 52-week range on file runs from $3.50 to $5.45. The most recent close on file for ABUS is $4.18, dated October 21, 2026. That is −$0.15 (−3.46%) against the previous close. The latest close sits 19.43% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $14.08M. Against the prior fiscal year total of $6.17M, that is a change of +128.21%. The same year closed with a net loss of $33.50M. Profit margin runs at 84.23%. That is 122.5 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 0.79.

Across the 4 fiscal years on file, revenue moves from $39.02M in 2022 to $14.08M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 5.29. That is 0.3 times the Biotechnology median of 16.6. The price-to-sales ratio is 3.53. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −6.70%. Across 10 years the annualized return works out at +2.55%. Beta against the wider market is reported at 0.76. Daily returns over the trailing 10 years annualize to a volatility of 85.27%.

Growth & Income

The record shows no dividend for ABUS.

2026 is still running; the total return is −13.10% year to date. Across the complete calendar years on file, 2017 returned +106.12% and 2022 returned −40.10%. Of the 9 complete calendar years on file, 6 finished higher.